U.S. Markets open in 7 hrs 15 mins

Medicenna Therapeutics Corp. (MDNA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4300-0.1000 (-2.83%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.5300
Open3.5000
Bid0.0000 x 3000
Ask0.0000 x 1100
Day's Range3.3500 - 3.5000
52 Week Range2.1950 - 6.8400
Volume62,922
Avg. Volume230,383
Market Cap182.499M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Medicenna's MDNA55 Data From Mid-Stage Brain Cancer Study Published In Peer-Reviewed Clinical Cancer Research
    Benzinga

    Medicenna's MDNA55 Data From Mid-Stage Brain Cancer Study Published In Peer-Reviewed Clinical Cancer Research

    Medicenna Therapeutics Corp (NASDAQ: MDNA) announced the peer-reviewed publication of clinical data from its Phase 2b trial evaluating MDNA55 in recurrent glioblastoma (rGBM). The Phase 2b trial evaluated MDNA55, an interleukin-4 (IL-4)-guided toxin, as a treatment for rGBM, the most common and uniformly fatal form of brain cancer. Results show that the median overall survival (OS) was 11.8 months, which is longer than what would be expected from the approved drugs carmustine (OS of 5.1 – 7.5 months), lomustine (OS of 7.1 – 9.8 months), or temozolomide (OS of 5.4 – 9.9 months). Notably, the data also shows a potential link between patients experiencing radiographic progression and those exhibiting insufficient MDNA55 penetration into the tumor, suggesting that at least a portion of patients who did not respond well to MDNA55 may have benefited from higher drug concentrations. These analyses supplement previously presented findings observed in Medicenna's proposed patient population showing an 81% tumor control rate (26/32) and a median OS of 15.7 months, which represents a >100% improvement compared to an external control arm (median OS of 7.2 months). Medicenna is currently pursuing a partnership strategy to facilitate MDNA55's further development through the planned Phase 3 clinical trial. Price Action: MDNA shares are up 5.4% at $3.7 during the market trading hours on the last check Friday. See more from BenzingaClick here for options trades from BenzingaAstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung CancerAcasti Pharma To Acquire Grace Therapeutics: Highlights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
    GlobeNewswire

    Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma

    -- Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma -- Medicenna’s proposed patient population shows a tumor control rate of 81% (26/32) based on modified RANO criteria TORONTO and HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the peer-reviewed publication of clinical data from the Company’s Phase 2b recurrent glioblastoma (rGBM) trial in Clinical Cancer Research. The paper, entitled “Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-enhanced Delivery of IL4R-targeted Immunotoxin MDNA55 in Recurrent Glioblastoma,” was published in collaboration with researchers at several prestigious institutions including University of California Los Angeles and Duke University. Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna, commented, “This Phase 2b trial has generated compelling data, and we are very pleased to have them published in such a prestigious peer-reviewed journal. In particular, we are highly encouraged by results showing that early determination of progression free survival (PFS) using modified RANO (mRANO) may be a strong surrogate for overall survival in rGBM. We believe this finding and the positive mRANO PFS and overall survival (OS) data from our proposed patient population bode well for the outcome of the planned Phase 3 trial, which utilizes an innovative open label hybrid design with OS as the primary endpoint. Medicenna is pursuing a partnership strategy to continue the Phase 3 development.” The Phase 2b trial evaluated MDNA55, an interleukin-4 (IL-4)-guided toxin, as a treatment for rGBM, the most common and uniformly fatal form of brain cancer. Results presented in the peer-reviewed paper show that the median OS of radiographically evaluable patients in the trial irrespective of dose or IL4R expression was 11.8 months, which is longer than what would be expected from the approved drugs carmustine (OS of 5.1 – 7.5 months)1,2, lomustine (OS of 7.1 – 9.8 months)3-5, or temozolomide (OS of 5.4 – 9.9 months)3,6,7. Notably, the data also show a potential link between patients experiencing radiographic progression and those exhibiting insufficient MDNA55 penetration into the tumor, suggesting that at least a portion of patients who did not respond well to MDNA55 may have benefited from higher drug concentrations. Additional analyses from the publication show that both locally and centrally determined PFS using mRANO criteria strongly correlated with OS, suggesting that the mRANO criteria may be superior to the standard RANO and iRANO at predicting OS, particularly for immunotherapies. These analyses supplement previously presented findings observed in Medicenna’s proposed patient population showing an 81% tumor control rate (26/32) based on mRANO and a median OS of 15.7 months, which represents a >100% improvement compared to an external control arm (median OS of 7.2 months). The proposed patient population included all MDNA55-treated trial participants with high IL4R expression and participants with low IL4R expression that received a high dose of MDNA55 treatment. Medicenna is currently pursuing a partnership strategy to facilitate MDNA55’s further development through the planned Phase 3 clinical trial. Following an End of Phase 2 meeting with the United States Food and Drug Administration (FDA), the agency agreed that Medicenna could conduct an open label hybrid Phase 3 trial that allows use of a substantial number of subjects (two-thirds) from a matched external control arm to support regulatory approval of MDNA55 for rGBM. The FDA also expressed their willingness to consider an interim analysis of the trial if certain criteria are met. Unlike conventional randomized control trials, the hybrid trial design will reduce the overall number of subjects needed in the study to achieve the primary endpoint as well as reduce the cost and timelines associated with completing the trial. References Brandes AA et al. Neurology 2004; 63: 1281–4.Reithmeier T et al. BMC Cancer 2010; 10: 30.Weller M et al. Neuro Oncol 2013; 15: 4–27.Wick W et al. J Clin Oncol 2010;28: 1168–74.Batchelor TT et al. J Clin Oncol 2013; 31: 3212–8.Balmaceda C et al. Cancer 2008;112: 1139–46.Wick A et al. J Clin Oncol 2007;25:3357–61. About Medicenna Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL-2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna’s early-stage program on Bifunctional SuperKine ImmunoTherapies (BiSKITs™) is designed to further enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively. Forward-Looking StatementThis news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts including statements related to a potential partnership for MDNA55. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and United States securities law. CONTACT: Further Information For further information about the Company please contact: Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com Investor Contact For more investor information, please contact: Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com

  • MDNA: Targeting ‘Cold’ Tumors with Dual Cytokine
    Zacks Small Cap Research

    MDNA: Targeting ‘Cold’ Tumors with Dual Cytokine

    By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Preclinical Data for MDNA19-MDNA413 Presented at AACR 2021 On April 12, 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced the presentation of preclinical data for MDNA19-MDNA413, an IL-2/IL-13 dual specific cytokine derived from the company’s BiSKITs™ (Bi-function SuperKines as ImmunoTherapies) platform. A